Lu Yuan

Lu Yuan

Auto-generated profile, based on publicly available information

Lu Yuan

The Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2024 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
YHYan-Bing Huang
Yan-Bing Huang
LYLu Yuan
Lu Yuan
XXXin-Yu Xiao
Xin-Yu Xiao
XWXiao-Ying Wang
Xiao-Ying Wang
SFSi-Jia Feng
Si-Jia Feng
HZHui Zheng
Hui Zheng

29 June 2024 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
LYLu Yuan
Lu Yuan
SQSi‐Jie Quan
Si‐Jie Quan
XLXin‐Yu Li
Xin‐Yu Li
YHYan‐Bing Huang
Yan‐Bing Huang
YLYan‐Qiu Li
Yan‐Qiu Li
HZHui Zheng
Hui Zheng

10 November 2024 in Journal of Nursing Scholarship
Verified
Journal Article
Closed access
LYLu Yuan
Lu Yuan
SQSi‐Jie Quan
Si‐Jie Quan
XLXin‐Yu Li
Xin‐Yu Li
BCBo‐Zhu Chen
Bo‐Zhu Chen
YHYan‐Bing Huang
Yan‐Bing Huang
HZHui Zheng
Hui Zheng

6 June 2026 in Journal of Neurology
Verified
Journal Article
Closed access
LYLu Yuan
Lu Yuan
YZYu-Xin Zhang
Yu-Xin Zhang
PKPantila Kulachai
Pantila Kulachai
XNXin-Ying Niu
Xin-Ying Niu
TYTing Yu
Ting Yu
HZHui Zheng
Hui Zheng

23 July 2026 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
LYLu Yuan
Lu Yuan
PKPantila Kulachai
Pantila Kulachai
QWQiao-Mei Wu
Qiao-Mei Wu
YZYu-Xin Zhang
Yu-Xin Zhang
XNXin-Ying Niu
Xin-Ying Niu
HZHui Zheng
Hui Zheng

23 September 2026 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
QWQiao-Mei Wu
Qiao-Mei Wu
HMHong-Lin Mei
Hong-Lin Mei
LYLu Yuan
Lu Yuan
YZYu-Xin Zhang
Yu-Xin Zhang
BLBei Lv
Bei Lv
HZHui Zheng
Hui Zheng
This Bayesian meta-analysis evaluated virtual reality (VR) therapy for substance use disorder (SUD). A total of 22 studies involving 2648 participants were included. VR-based therapy reduced substance craving compared to controls (standardized mean difference (SMD) = − 0.75, 95% credible intervals (CrI): −1.72 to 0.00, posterior probability (PP) = 83.30%, inclusion Bayes factor (BF) = 5.00, tau(τ) = 1.26). Subgroup analyses showed that VR aversion therapy (VR-AT), the illicit substance use disorder (ISUD) subgroup, and single-session within 30 minutes each demonstrated significant reductions in craving. Craving reductions showed little difference across immersion levels, and meta-regression found no reliable linear/non‑linear relationship between total VR duration and efficacy. Leave-one-out and prior sensitivity analyses confirmed the robustness of the results. VR improved executive function (SMD = −0.53, 95% CrI: −1.89 to 0.00, PP = 79.70%, inclusion BF = 3.94, τ = 0.11) and reduced anxiety symptoms (SMD = −0.33, 95% CrI: −0.72 to 0.00, PP = 85.90%, inclusion BF = 6.11, τ = 0.08). Evidence quality was low for all outcomes. No credible evidence supported its superiority over controls in abstinence rate, self-efficacy, depression, or dropout rate. Substantial heterogeneity across effect estimates highlights the need for additional high-quality RCTs.